Correct me if I'm wrong but the FXTAS stuff is new.
With a market of roughly 1 in 2000 adults over 50 I do believe this represents the first real sign of NEU moving into a broader market (as opposed to intimations with 2591). That's interesting.
By the sounds of it they're looking to do some preclinical tests (mouse models) but then presumably would jump straight to Phase II or maybe even Phase III (safety trials seem superfluous at this stage).
Good to see the army stuff with TBI is still in the mix. An outside chance of a big price jump would be a new trial funded by the army.
And lots of discussions in the report about efficacy signals in Ph III trials, clearly designed to settle down some of the more nervous.
Looking good for now.
NEU Price at posting:
6.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)